Public Funding for Optosense Ltd

Project title: Real-Time CTC Profiling for Enhanced Breast Cancer Treatment Decisions Our solution uses innovative microfluidic technology to enhance breast cancer treatment by precisely detecting and profiling CTCs for targeted ADC therapies. This approach aims to improve patient outcomes and reduce healthcare costs by providing real-time, accurate guidance for selecting the most effective ADC treatments. 11.6% of all cancers diagnosed were female breast cancer, making it the second most common cancer worldwide in 2022 Current ADC treatments like T-DM1 and T-DXd show promise but require precise targeting of cancer cells, which existing detection methods struggle to achieve due to limitations in sensitivity, specificity, and cost. This project aligns with the urgent need for more precise cancer treatments and supports the NHS Long Term Plan of leveraging personalised medicine for cancer prevention, diagnosis, and treatment. By developing this advanced technology, the project aims to transform breast cancer treatment, improving patient management and outcomes while reducing the economic burden on healthcare systems.